Tian-Yu Lian
Overview
Explore the profile of Tian-Yu Lian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF
Cheng C, Lian T, Zhu X, Virdone S, Sun K, Camm J, et al.
Open Heart
. 2025 Feb;
12(1).
PMID: 39914996
Background: Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial fibrillation (AF) have been sparsely investigated. Objective: To provide a contemporary prospective comparison...
2.
Shen Y, Ding D, Lian T, Qiu B, Yan Y, Wang P, et al.
J Mol Cell Cardiol
. 2024 Oct;
197:61-77.
PMID: 39437884
Pulmonary arterial hypertension (PAH) is a fatal lung disease characterized by progressive pulmonary vascular remodeling. The initial cause of pulmonary vascular remodeling is the dysfunction of pulmonary arterial endothelial cells...
3.
Zhang Z, Liu C, Ma J, Ma J, Wang J, Li R, et al.
J Am Coll Cardiol
. 2024 Sep;
84(12):1092-1103.
PMID: 39260931
Background: B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide is the only blood biomarker in established risk calculators for pulmonary arterial hypertension (PAH). Profiling systemic-originated plasma immunoglobulin G (IgG) N-glycans,...
4.
Wang J, Liu C, Huang S, Wang H, Cheng C, Ma J, et al.
Eur J Pharmacol
. 2024 Mar;
970:176492.
PMID: 38503401
Pulmonary arterial hypertension (PAH) is a progressive vascular disease characterized by remodeling of the pulmonary vasculature and elevated pulmonary arterial pressure, ultimately leading to right heart failure and death. Despite...
5.
Liu C, Zhou Y, Lian T, Li R, Ma J, Yang Y, et al.
Hypertension
. 2023 Dec;
81(2):372-382.
PMID: 38116660
Background: The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) is multifactorial and growing evidence has indicated that hematological disorders are involved. Clonal hematopoiesis of indeterminate potential (CHIP) has recently been...
6.
He Y, Wang Y, Ma J, Li R, Wang J, Lian T, et al.
Vascul Pharmacol
. 2023 Sep;
153:107216.
PMID: 37699495
Pulmonary arterial hypertension (PAH) is a complex and progressive disease characterized by pulmonary arterial remodeling. Despite that current combination therapy has shown improvement in morbidity and mortality, a better deciphering...
7.
Zhu X, Liu Z, Wang P, Wang J, Wen S, Zhang J, et al.
Res Pract Thromb Haemost
. 2023 Sep;
7(6):102157.
PMID: 37674867
Background: Various inherited traits contribute to the overall risk of venous thromboembolism (VTE). In addition, the epidemiology of thrombophilia in the East-Asian VTE population remains unclear; thus, we aimed to...
8.
Zhang Z, Wang H, Lian T, Zhou Y, Xu X, Guo F, et al.
Hypertension
. 2023 Jul;
80(9):1929-1939.
PMID: 37449418
Background: The pathological mechanism of chronic thromboembolic pulmonary hypertension (CTEPH) is not fully understood, and inflammation has been reported to be one of its etiological factors. IgG regulates systemic inflammatory...
9.
10.
Lian T, Zhou Y, Zhu Y, Guo F, Jing Z
JACC Asia
. 2023 Jan;
2(5):651.
PMID: 36624797
No abstract available.